Renaissance Group LLC Reduces Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Renaissance Group LLC trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 5.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 212,128 shares of the company's stock after selling 11,836 shares during the quarter. Renaissance Group LLC owned approximately 0.10% of Hims & Hers Health worth $5,129,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after buying an additional 4,145,305 shares in the last quarter. State Street Corp increased its stake in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after acquiring an additional 206,078 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Remove Ads

Analyst Ratings Changes

HIMS has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Truist Financial reduced their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday. Finally, Piper Sandler increased their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $38.25.

Hims & Hers Health Trading Up 1.2 %

HIMS traded up $0.32 during trading hours on Friday, hitting $27.13. 16,210,541 shares of the company's stock were exchanged, compared to its average volume of 15,146,132. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market cap of $6.03 billion, a P/E ratio of 61.66 and a beta of 1.65. The firm has a 50 day moving average of $38.75 and a 200 day moving average of $30.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Melissa Baird sold 33,337 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total value of $910,766.84. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares of the company's stock, valued at $21,994,867.56. This trade represents a 3.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 835,884 shares of company stock worth $31,659,701. Company insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.